Table 2.
Characteristics of subjects according to fasting glucose
| Variable | Subjects with fasting glucose < 100 mg/dL (n = 76) | Subjects with fasting glucose ≥100 mg/dL and < 126 mg/dL (n = 19) | Subjects with T2DM (n = 11) | p |
|---|---|---|---|---|
| Sex (male: n, %) | 41, 53.9 | 9, 47.4 | 5, 45.5 | 0.721 |
| Cigarette (yes: n, %) | 22, 28.9 | 4, 26.7 | 3, 30 | 0.663 |
| CML (n, %) | 59, 80.8 | 13, 72.2 | 10, 90.9 | 0.747 |
| GIST (n, %) | 14, 18.4 | 5, 27.8 | 1, 9.1 | |
| Age (years) | 38.6 ± 15.7 | 41.8 ± 16.8 | 53 ± 14.2 | 0.023 |
| Weight (kg) | 70.5 ± 15.1 | 64.2 ± 14.4 | 65.3 ± 10.7 | 0.486 |
| Weight (after 1 month, kg) | 69.6 ± 14.9 | 63.7 ± 12.6 | 74.4 ± 27.5 | 0.645 |
| Weight (after 6 months, kg) | 74.9 ± 16.6 | 78.5 ± 10 | 61.6 ± 7.5 | 0.127 |
| Mg (mg/dL) | 2.2 ± 0.25 | 2 ± 0.20 | 2.1 ± 0.38 | 0.098 |
| Mg (after 1 month, mg/dL) | 2 ± 0.6 | 1.9 ± 0.18 | 2.25 ± 0.21 | 0.343 |
| Creatinine (before, mg/dL) | 0.90 (0.68–1) | 1.02 (0.62–1.13) | 1.02 (0.75–1.12) | 0.260 |
| Creatinine (after 1 month, mg/dL) | 0.81 (0.70–0.90) | 0.94 (0.68–1.05) | 0.90 (0.60–1.10) | 0.549 |
| Creatinine (after 6 months, mg/dL) | 0.86 (0.73–0.99) | 0.84 (0.58–1.06) | 0.84 (0.73–0.98) | 0.239 |
| ALT (before, U/L) | 23.6 (14–26.5) | 45.8 (14.2–48.2) | 31 (17–48.5) | 0.293 |
| ALT (after 1 month, U/L) | 24.9 (15–30) | 51.3 (19–54.7) | 17.8 (13–23.5) | 0.008 |
| ALT (after 6 months, U/L) | 22.3 (17–26) | 23.4 (20–27.5) | 16. 5 (15.2–17.7) | 0.106 |
p value was obtained with Kruskal-Wallis or chi-square test
CML chronic myeloid leukemia, GIST gastrointestinal stromal tumor, IFG impaired fasting glucose, Mg magnesium, ALT alanine aminotransferase